Monte Rosa ( GLUE ) Q2 Revenue Jumps 394%
Monte Rosa Therapeutics ( NASDAQ:GLUE ) , a biotechnology company developing molecular glue degrader therapies, announced results for the second quarter on August 7, 2025. The standout news was a sharp jump in GAAP revenue, which reached $23.2 million, well above GAAP expectations of $7.4 million.
Monte Rosa Therapeutics ( GLUE ) Reports Q2 Loss, Tops Revenue Estimates
Monte Rosa Therapeutics (GLUE) delivered earnings and revenue surprises of +51.61% and +118.09%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Certara, Inc. ( CERT ) Q2 Earnings Miss Estimates
Certara (CERT) delivered earnings and revenue surprises of -30.00% and +0.98%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Monte Rosa Therapeutics Announces First Subjects Dosed in Phase 1 Study of MRT-8102, a NEK7-Directed Molecular Glue Degrader for the Treatment of Multiple Inflammatory Diseases - Monte Rosa Therapeutics ( NASDAQ:GLUE )
MRT-8102 Phase 1 study includes single and multiple ascending dose cohorts in healthy volunteers and is designed to evaluate safety, pharmacokinetics, NEK7 protein degradation, and other key downstream pharmacodynamic markers; initial results anticipated in H1 2026
Monte Rosa Therapeutics Announces First Subjects Dosed in Phase 1 Study of MRT-8102, a NEK7-Directed Molecular Glue Degrader for the Treatment of Multiple Inflammatory Diseases
Monte Rosa Therapeutics Announces First Subjects Dosed in P1 Study of MRT-8102, a NEK7-Directed Molecular Glue Degrader ...
Monte Rosa Therapeutics Announces FDA Clearance of IND Application for MRT-8102, a NEK7-Directed Molecular Glue Degrader for the Treatment of Multiple Inflammatory Diseases
Monte Rosa Therapeutics Announces FDA Clearance of IND Application for MRT-8102, a NEK7-Directed Molecular Glue Degrader for the Treatment of Multiple Inf ...
Monte Rosa Therapeutics Announces FDA Clearance of IND Application for MRT-8102, a NEK7-Directed Molecular Glue Degrader for the Treatment of Multiple Inflammatory Diseases - Monte Rosa Therapeutics ( NASDAQ:GLUE )
MRT-8102, a highly selective NEK7-directed molecular glue degrader ( MGD ) developed to treat inflammatory conditions linked to NLRP3, IL-1β, and IL-6 dysregulation, expands Monte Rosa's clinical I&I portfolio
Wall Street Analysts Think Monte Rosa Therapeutics ( GLUE ) Could Surge 222.16%: Read This Before Placing a Bet
The mean of analysts' price targets for Monte Rosa Therapeutics (GLUE) points to a 222.2% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Monte Rosa Therapeutics to Participate in the Jefferies Global Healthcare Conference - Monte Rosa Therapeutics ( NASDAQ:GLUE )
BOSTON, May 28, 2025 ( GLOBE NEWSWIRE ) -- Monte Rosa Therapeutics, Inc. GLUE, a clinical-stage biotechnology company developing novel molecular glue degrader ( MGD ) -based medicines, today announced that Markus Warmuth, M.D., Chief Executive Officer, will participate in a fireside chat at the ...
Monte Rosa Therapeutics ( GLUE ) Tops Q1 Earnings and Revenue Estimates
Monte Rosa Therapeutics (GLUE) delivered earnings and revenue surprises of 337.50% and 235.52%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
TScan Therapeutics, Inc. ( TCRX ) Reports Q1 Loss, Tops Revenue Estimates
TScan Therapeutics (TCRX) delivered earnings and revenue surprises of 7.14% and 34.43%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Arvinas, Inc. ( ARVN ) Q1 Earnings and Revenues Beat Estimates
Arvinas (ARVN) delivered earnings and revenue surprises of 232.56% and 332.53%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Monte Rosa Therapeutics Presents Preclinical Data at American Association for Cancer Research ( AACR ) Annual Meeting 2025 on the Potential of its CDK2-directed Molecular Glue Degrader to Treat HR-positive/HER2-negative Breast Cancer
Monte Rosa Therapeutics Presents Preclinical Data at American Association for Cancer Research (AACR) Annual Meeting ...
Novartis Partner Monte Rosa Therapeutics Touts Positive Data From Early-Stage Study Of Investigational Drug Candidate For Immune-Mediated Disorders - Monte Rosa Therapeutics ( NASDAQ:GLUE )
MRT-6160 achieves over 90% VAV1 degradation in T and B cells. Monte Rosa's $150 million deal with Novartis could bring up to $2.1 billion in milestone payments. Feel unsure about the market's next move? Copy trade alerts from Matt Maley-a Wall Street veteran who consistently finds profits in ...
Monte Rosa Therapeutics ( GLUE ) Q4 Earnings and Revenues Top Estimates
Monte Rosa Therapeutics (GLUE) delivered earnings and revenue surprises of 162.16% and 374.06%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?
Monte Rosa Therapeutics to Present Pipeline Update and Release Fourth Quarter and Full Year 2024 Financial Results on March 20, 2025 - Monte Rosa Therapeutics ( NASDAQ:GLUE )
Company to present clinical results from Phase 1 SAD/MAD study of VAV1-directed molecular glue degrader MRT-6160 and Phase 1/2 study of MRT-2359 in MYC-driven solid tumors Conference call and webcast planned for 8 a.m. ET on March 20, 2025 BOSTON, March 11, 2025 ( GLOBE NEWSWIRE ) -- Monte Rosa ...
3 Top Cancer Biotechs to Keep An Eye On in 2025
If the cancer space appeals to you, it's time to consider stocks like Novartis, Exact Sciences and Monte Rosa.
Monte Rosa Therapeutics Provides Corporate Update and Key Anticipated Milestones for 2025 - Monte Rosa Therapeutics ( NASDAQ:GLUE )
Initial clinical data from Phase 1 SAD/MAD study of VAV1-directed molecular glue degrader ( MGD ) MRT-6160 expected in Q1 2025 Additional clinical results from Phase 1/2 study of MRT-2359 in MYC-driven solid tumors, including biomarker and activity data, anticipated in Q1 2025
Monte Rosa Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference - Monte Rosa Therapeutics ( NASDAQ:GLUE )
BOSTON, Jan. 06, 2025 ( GLOBE NEWSWIRE ) -- Monte Rosa Therapeutics, Inc. GLUE, a clinical-stage biotechnology company developing novel molecular glue degrader ( MGD ) -based medicines, today announced that Markus Warmuth, M.D., Chief Executive Officer, will present at the 43rd Annual J.P.
Monte Rosa Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference
BOSTON, Jan. 06, 2025 ( GLOBE NEWSWIRE ) -- ( Nasdaq: GLUE ) , a clinical-stage biotechnology company developing novel molecular glue degrader ( MGD ) -based medicines, today announced that Markus Warmuth, M.D., Chief Executive Officer, will present at the 43rd Annual J.P.
Buy 5 Genomics & Synthetic Biology Stocks Likely to Soar in Short Term
These five geonomics and synthetic biology stocks are likely to soar in the short-term. They Are: CRSP, IMCR, GLUE, RIGL, CSTL.
Monte Rosa Therapeutics Appoints Dr. Eric A. Hughes to Board of Directors
BOSTON, Dec. 13, 2024 ( GLOBE NEWSWIRE ) -- Monte Rosa Therapeutics, Inc. ( Nasdaq: GLUE ) , a clinical-stage biotechnology company developing novel molecular glue degrader ( MGD ) -based medicines, today announced the appointment of Eric A. Hughes, M.D, Ph.D., to its Board of Directors.
Monte Rosa Therapeutics Appoints Dr. Eric A. Hughes to Board of Directors - Monte Rosa Therapeutics ( NASDAQ:GLUE )
BOSTON, Dec. 13, 2024 ( GLOBE NEWSWIRE ) -- Monte Rosa Therapeutics, Inc. GLUE, a clinical-stage biotechnology company developing novel molecular glue degrader ( MGD ) -based medicines, today announced the appointment of Eric A. Hughes, M.D, Ph.D., to its Board of Directors.
Monte Rosa Therapeutics Announces Closing of Global License Agreement with Novartis to Advance T and B Cell-modulating VAV1-directed Molecular Glue Degraders
Monte Rosa Therapeutics Announces Closing of Global License Agreement with ...
Monte Rosa Therapeutics Presents Preclinical Data at the 2024 San Antonio Breast Cancer Symposium on the Potential of its CDK2-directed Molecular Glue Degraders to Treat HR-positive/HER2-negative Breast Cancer
Monte Rosa Therapeutics Presents Preclinical Data at the 2024 San Antonio Breast Cancer Symposium on the Potential of its CDK2-directed Molecular Glue ...
Monte Rosa Therapeutics Provides Development Progress Update for Ongoing MRT-2359 Phase 1/2 Study in Patients with MYC-driven Solid Tumors
Results from dose escalation arms of Phase 1/2 study of MRT-2359 demonstrated a favorable safety profile and targeted levels of GSPT1 degradation using a 21 days on, 7 days off drug dosing schedule in heavily pretreated solid tumor patients
Wall Street Analysts See a 64.09% Upside in Monte Rosa Therapeutics ( GLUE ) : Can the Stock Really Move This High?
The mean of analysts' price targets for Monte Rosa Therapeutics (GLUE) points to a 64.1% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Monte Rosa Therapeutics to Participate in the Piper Sandler Healthcare Conference
BOSTON, Nov. 26, 2024 ( GLOBE NEWSWIRE ) -- ( Nasdaq: GLUE ) , a clinical-stage biotechnology company developing novel molecular glue degrader ( MGD ) -based medicines, today announced that Markus Warmuth, M.D., Chief Executive Officer, will participate in a fireside chat at the 36th Annual ...
Wall Street Analysts Think Monte Rosa Therapeutics ( GLUE ) Could Surge 100.47%: Read This Before Placing a Bet
The mean of analysts' price targets for Monte Rosa Therapeutics (GLUE) points to a 100.5% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Monte Rosa Therapeutics ( GLUE ) Reports Q3 Loss, Tops Revenue Estimates
Monte Rosa Therapeutics (GLUE) delivered earnings and revenue surprises of 35.56% and 103.13%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
Are You Looking for a Top Momentum Pick? Why Monte Rosa Therapeutics ( GLUE ) is a Great Choice
Does Monte Rosa Therapeutics (GLUE) have what it takes to be a top stock pick for momentum investors? Let's find out.
Wall Street Analysts Believe Monte Rosa Therapeutics ( GLUE ) Could Rally 67.24%: Here's is How to Trade
The average of price targets set by Wall Street analysts indicates a potential upside of 67.2% in Monte Rosa Therapeutics (GLUE). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the ...
Novartis Ag ( NVS ) Q3 2024 Earnings Call Transcript
NVS earnings call for the period ending September 30, 2024.
PROCEPT BioRobotics Posts Strong Q3 Earnings, Joins Monte Rosa Therapeutics, EyePoint Pharmaceuticals And Other Big Stocks Moving Higher On Monday - PROCEPT BioRobotics ( NASDAQ:PRCT )
U.S. stocks were higher, with the Dow Jones index gaining around 200 points on Monday. Shares of PROCEPT BioRobotics Corporation PRCT rose sharply during Monday's session after the company reported better-than-expected third-quarter financial results and raised its FY24 revenue guidance.
Why Is Monte Rosa Therapeutics Stock Surging On Monday? - Monte Rosa Therapeutics ( NASDAQ:GLUE ) , Novartis ( NYSE:NVS )
Monte Rosa Therapeutics Inc GLUE stock is trading higher on Monday after the company announced a global exclusive development and commercialization license agreement with Novartis AG NVS to advance VAV1 MGDs, including MRT-6160.
Monte Rosa Therapeutics Announces Global License Agreement with Novartis to Advance T and B Cell-modulating VAV1-directed Molecular Glue Degraders
Agreement expected to accelerate MRT-6160 clinical development and broadly explore therapeutic opportunities across multiple indications Monte Rosa to receive up-front payment of $150 million and is eligible to receive milestone payments, U.S. profit and loss share, and tiered royalties on ...
Monte Rosa Therapeutics to Participate in Upcoming Investor Conferences
BOSTON, Aug. 28, 2024 ( GLOBE NEWSWIRE ) -- ( Nasdaq: GLUE ) , a clinical-stage biotechnology company developing novel molecular glue degrader ( MGD ) -based medicines, today announced that management will participate in the following investor conferences: • 2024 Wells Fargo Healthcare ... ET.
Monte Rosa Therapeutics Announces First Participants Dosed in MRT-6160 Phase 1 Study
MRT-6160, a potent and highly selective VAV1-directed molecular glue degrader, represents a potential novel therapeutic approach for systemic and neurological autoimmune and inflammatory diseases
Monte Rosa Therapeutics Announces First Participants Dosed in MRT-6160 Phase 1 Study - Monte Rosa Therapeutics ( NASDAQ:GLUE )
MRT-6160, a potent and highly selective VAV1-directed molecular glue degrader, represents a potential novel therapeutic approach for systemic and neurological autoimmune and inflammatory diseases Initial Phase 1 clinical results, including biomarker data to demonstrate pharmacodynamic effects, ...
Monte Rosa Therapeutics ( GLUE ) Reports Q2 Loss, Tops Revenue Estimates
Monte Rosa Therapeutics (GLUE) delivered earnings and revenue surprises of 14% and 46.58%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Monte Rosa Therapeutics Announces Second Quarter 2024 Financial Results and Provides Corporate Update
IND clearance achieved for MRT-6160, a VAV1-directed MGD in development for systemic and neurological autoimmune diseases; on track to initiate Phase 1 SAD/MAD study this summer with initial clinical data expected in Q1 2025
ADARx Pharmaceuticals Appoints Ajim Tamboli, CFA as Chief Financial Officer
SAN DIEGO, July 30, 2024 ( GLOBE NEWSWIRE ) -- ADARx Pharmaceuticals, Inc. ( ADARx ) , a clinical stage biotechnology company developing next generation RNA therapeutics, today announced the appointment of Ajim Tamboli as Chief Financial Officer ( CFO ) .
Molecular Glues Clinical Trial Pipeline Appears Robust With 10+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight
The molecular glues pipeline and clinical trial analysis report delivers important insights on ongoing research, clinical strategies, upcoming therapeutics, and commercial analysis.
Monte Rosa Therapeutics to Present at the UBS Targeted Protein Degradation Day - Monte Rosa Therapeutics ( NASDAQ:GLUE )
BOSTON, July 08, 2024 ( GLOBE NEWSWIRE ) -- Monte Rosa Therapeutics, Inc.
Monte Rosa Therapeutics to Present at the UBS Targeted Protein Degradation Day
BOSTON, July 08, 2024 ( GLOBE NEWSWIRE ) -- Monte Rosa Therapeutics, Inc. ( Nasdaq: GLUE ) , a clinical-stage biotechnology company developing novel molecular glue degrader ( MGD ) -based medicines, today announced that Markus Warmuth, M.D., Chief Executive Officer, will participate in a ... ET.
Monte Rosa Therapeutics Presents Preclinical Data at EULAR 2024 Demonstrating Therapeutic Potential of MRT-6160 for the Treatment of Rheumatoid Arthritis
MRT-6160, a VAV1-directed molecular glue degrader ( MGD ) , inhibits disease progression, pro-inflammatory cytokines and autoantibody production in a model of rheumatoid arthritis Initiation of MRT-6160 Phase 1 SAD/MAD study anticipated in mid-year 2024 with initial clinical data expected in Q1 ...
Monte Rosa Therapeutics Announces Leadership Team Promotions - Monte Rosa Therapeutics ( NASDAQ:GLUE )
BOSTON, May 30, 2024 ( GLOBE NEWSWIRE ) -- Monte Rosa Therapeutics, Inc. GLUE, a clinical-stage biotechnology company developing novel molecular glue degrader ( MGD ) -based medicines, today announced three leadership team promotions effective immediately: Sharon Townson, Ph.D., to Chief ...
Monte Rosa Therapeutics Presents Preclinical Data at Digestive Disease Week 2024 Highlighting Therapeutic Potential of MRT-6160 in Inflammatory Bowel Disease
Monte Rosa Therapeutics Presents Preclinical Data at Digestive Disease Week 2024 Highlighting Therapeutic Potential of ...
Monte Rosa Therapeutics Announces First Quarter 2024 Financial Results and Provides Corporate Update - Monte Rosa Therapeutics ( NASDAQ:GLUE )
MRT-2359, a molecular glue degrader ( MGD ) being developed for MYC-driven solid tumors, advancing in ongoing Phase 1/2 clinical trial; determination of recommended Phase 2 dose expected in Q2 2024; Phase 1 clinical data anticipated in H2 2024
Recent Price Trend in Monte Rosa Therapeutics ( GLUE ) is Your Friend, Here's Why
Monte Rosa Therapeutics (GLUE) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.
